Oxidative stress and antioxidant status in prostate cancer patients: Relation to Gleason score, treatment and bone metastasis

Biomedicine and Pharmacotherapy

Volumn 65, Issue 7, 2011, Pages 516-524

  Battisti, Vanessa ^a   Maders, Liési D K ^a   Bagatini, Margarete D ^a   Reetz, Luiz Gustavo B ^a   Chiesa, Juarez ^a   Battisti, Iara E ^b   Gonçalves, Jamile F ^c   Duarte, Marta M F ^a   Schetinger, Maria R C ^a   Morsch, Vera M ^a  

^a FEDERAL UNIVERSITY OF SANTA MARIA   (Brazil)

^b UNIVERSIDADE FEDERAL DA FRONTEIRA SUL   (Brazil)

^c FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

Antioxidants; Oxidative stress; Prostate cancer

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; CATALASE; CYPROTERONE ACETATE; GOSERELIN; PROTEIN; SUPEROXIDE DISMUTASE; THIOBARBITURIC ACID REACTIVE SUBSTANCE; THIOL;

AGED; ANTIOXIDANT ACTIVITY; ARTICLE; BONE METASTASIS; CANCER PATIENT; CANCER THERAPY; CONTROLLED STUDY; ERYTHROCYTE; GLEASON SCORE; HUMAN; LIPID PEROXIDATION; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BLOOD LEVEL; PROTEIN CARBONYLATION; VITAMIN BLOOD LEVEL;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; ASCORBIC ACID; BONE NEOPLASMS; CATALASE; CYPROTERONE ACETATE; ERYTHROCYTES; GOSERELIN; HUMANS; LIPID PEROXIDATION; MALE; MIDDLE AGED; NEOPLASM GRADING; OXIDATIVE STRESS; PROSTATIC NEOPLASMS; PROTEIN CARBONYLATION; SULFHYDRYL COMPOUNDS; SUPEROXIDE DISMUTASE; THIOBARBITURIC ACID REACTIVE SUBSTANCES; VITAMIN E;

EID: 80755153057     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2011.06.003     Document Type: Article

References (47)

1. Parkin D.M., Bray F., Ferlay J., Pisani P. Global Cancer Statistics 2002. CA Cancer J Clin 2005, 55:74-108.
2. Gleason D.F Classification of prostatic carcinomas. Cancer Chemother Rep 1966, 50:125-128.
3. Gleason D.F. Histologic grading of prostate cancer: a perspective. Hum Pathol 1992, 23:273-279.
4. Chao T.Y., Wu Y.Y., Janckila A.J. Tartrate-resistant acid phosphatase isoform 5b (TRACP 5b) as a serum maker for cancer with bone metastasis. Clin Chim Acta 2010, 411:1553-1564.
5. Anderson J., Sternberg C.N., Kannan K., Jain S.K. Oxidative stress and apoptosis. Pathophysiology 2000, 7:153-163.
6. Anderson J. Treatment of prostate cancer - The role of primary hormonal therapy. EAU Update Ser 2003, 1:32-39.
7. Ripple M.O., Henry W.F., Rago R.P., Wilding G. Prooxidant-antioxidant shift induced by androgen treatment of human prostate carcinoma cells. J Natl Cancer Inst 1997, 89:40-48.
8. Khandrika L., Kumar B., Koul S., Maroni P., Koul H.K. Oxidative stress in prostate cancer. Cancer Lett 2009, 282:125-136.
9. Ames B.N., Shigenaga M.K., Hagen T.M. Oxidants, antioxidants and the degenerative diseases of aging. Proc Natl Acad Sci U S A 1993, 90:7915-7922.
10. Dargel R. Lipid peroxidation-a common pathogenetic mechanism?. Exp Toxic Pathol 1992, 44:169-181.
11. Barouki Y.M. Repression of gene expression by oxidative stress. Biochem J 1999, 342:481-496.
12. Al-Gadani Y., El-Ansary A., Attas O., Al-Ayadhi L. Metabolic biomarkers related to oxidative stress and antioxidant status in Saudi autistic children. Clin Biochem 2009, 42:1032-1040.
13. Battisti V., Maders L.D., Bagatini M.D., Santos K.F., Spanevello R.M., Maldonado P.A., et al. Measurement of oxidative stress and antioxidant status in acute lymphoblastic leukemia patients. Clin Biochem 2008, 41:511-518.
14. Pryor W.A., Vitamin E and heart disease: basic science to clinical intervention trials. Free Radic Biol Med 2000, 28:141-164.
15. Smirnoff N. L-ascorbic acid biosynthesis. Vitam Horm 2001, 61:241-266.
16. Maldonado P.A., Negrini L.A., Kaizer R.R., Zanin R.F., Araújo M.C., Battisti V., et al. Oxidative status in patients submitted to conization and radiation treatments for uterine cervix neoplasia. Clin Chim Acta 2006, 366:174-178.
17. Jentzsch A.M., Bachmann H., Furst P., Biesalski H.K. Improved analysis of malondialdehyde in human body fluids. Free Radic Biol Med 1996, 20:251-256.
18. Levini R.L., Garland D., Oliver C.N., Amici A., Climent I., Lenz A. Determination of carbonyl content in oxidatively modified proteins. Methods Enzymol 1990, 186:464-478.
19. 2 solutions in the UV). Anal Biochem 1972, 49:474-478.
20. Mc Cord J.M., Fridovich I. Superoxide dismutase: an enzymatic function for erythrocuprein (hemocuprein). J Biol Chem 1969, 244:6049-6055.
21. Ellman G.L. Tissue sulfhydryl groups. Arch Biochem Biophys 1959, 82:70-77.
22. Jacques-Silva M.C., Nogueira C.W., Broch L.C., Flores E.M.M., Rocha J.B.T. Diphenil diselenide and ascorbic changes deposition of selenium and ascorbic acid in liver and brain of mice. Pharmacolol Toxicol 2001, 88:119-125.
23. Hansen L.G., Warwick W.J. A fluorometric micromethod for serum vitamins A and E. Am J Clin Pathol 1969, 51:538-541.
24. Bradford M.M. A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976, 72:218-254.
25. Fleshner N.E., Klotz L.H. Diet, androgens, oxidative stress and prostate cancer susceptibility. Cancer Metastasis Rev 1999, 17:325-330.
26. Goswami K., Nandeesha H., Koner B.C., Nandakumar D.N. A comparative study of serum protein-bound sialic acid in benign and malignant prostatic growth: possible role of oxidative stress in sialic acid homeostasis. Prostate Cancer Prostatic Dis 2007, 10(4):356-359.
27. Yilmaz M.I., Saglam K., Sonmez A., Gok D.E., Basal S., Kilic S., et al. Antioxidant system activation in prostate cancer. Biol Trace Elem Res 2004, 98:13-19.
28. Baker A.M., Oberley L.W., Cohen M.B. Expression of antioxidant enzymes in human prostatic adenocarcinoma. Prostate 1997, 32:229-233.
29. Bostwick D.G., Alexander E.E., Singh R., Shan A., Qian J., Santella R.M., et al. Antioxidant enzyme expression and reactive oxygen species damage in prostatic intraepithelial neoplasia and cancer. Cancer 2000, 89:123-134.
30. Arsova-Sarafinovska Z., Eken A., Matevska N. Increased oxidative/nitrosative stress and decreased antioxidant enzyme activities in prostate cancer. Clin Biochem 2009, 42:1228-1235.
31. Klein E.A., Casey G., Silverman R. Genetic susceptibility and oxidative stress in prostate cancer: integrated model with implications for prevention. Urology 2006, 68:1145-1151.
32. Pinho R.A., Andrades M.E., Oliveira M.R. Imbalance in SOD/CAT activities in rat skeletal muscles submitted to treadmill training exercise. Cell Biol Int 2006, 30:848-853.
33. OByrne K.J., Dalgleish A.G. Chronic immune activation and inflammation as the cause of malignancy. Br J Cancer 2001, 85:473-483.
34. Visner G.A., Dougall W.C., Wilson J.M., Burr I.A., Nick H.S. Regulation of manganese superoxide dismutase by lipopolysaccharide, interleukin-1, and tumor necrosis factor. Role in the acute inflammatory response. J Biol Chem 1990, 265:2856-2864.
35. Keno Y., Fridovich I. Superoxide radical inhibits catalase. J Biol Chem 1997, 257:5751-5754.
36. Chiou J.F., Hu M.L. Elevated lipid peroxidation and disturbed antioxidant enzyme activities in plasma and erythrocytes of patients with uterine cervicitis and myoma. Clin Biochem 1999, 32:189-192.
37. Huang H.Y., Alberg A.J., Norkus E.P., Hoffman S.C., Comstock G.W., Helzlsouer K.J. Prospective study of antioxidant micronutrients in the blood and the risk of developing prostate cancer. Am J Epidemiol 2003, 157:335-344.
38. Pathak S.K., Sharma R.A., Mellon J.K. Chemoprevention of prostate cancer by dietderivedantioxidant agents and hormonal manipulation. Int J Oncol 2003, 22:5-13.
39. Miyake H., Hara I., Kamidono S., Eto H. Oxidative DNA damage in patients with prostate cancer and its response to treatment. J Urol 2004, 171:1533-1536.
40. Nishikawa M. Reactive oxygen species in tumor metastasis. Cancer Lett 2008, 266:53-59.
41. Xie K., Huang S. Regulation of cancer metastasis by stress pathways. Clin Exp Metastasis 2003, 20:31-43.
42. Yamamoto T., Terada N., Seiyama A., Nishizawa Y., Akedo H., Kosaka H. Increase in experimental pulmonary metastasis in mice by l-arginine under inhibition of nitric oxide production by NG-nitro-l-arginine methyl ester. Int J Cancer 1998, 75:140-144.
43. Iwasaki T., Higashiyama M., Kuriyama K., Sasaki A., Mukai M., Shinkai K., et al. NG-nitrol- arginine methyl ester inhibits bone metastasis after modified intracardiac injection of human breast cancer cells in a nude mouse model. Jpn J Cancer Res 1997, 88:861-866.
44. Nishikawa M., Hashida M. Inhibition of tumour metastasis by targeted delivery of antioxidant enzymes. Expert Opin Drug Deliv 2006, 3:355-369.
45. Vis A.N., Roemeling S., Kranse R., Schröder F.H., Kwast T.H.V. Should we replace the Gleason score with the amount of high-grade prostate cancer?. Eur Urol 2007, 51:931-939.
46. Chan J.M., Stampfer M.J., Ma J., Rimm E.B., Willett W.C., Giovannucci E.L. Supplemental vitamin E intake and prostate cancer risk in a large cohort of men in the United States. Cancer Epidemiol Biomarkers Prev 1999, 8:893-899.
47. Yossepowitch O., Pinchuk I., Gur U., Neumann A., Lichtenberg D., Baniel J. Advanced but not localized prostate cancer is associated with increased oxidative stress. J Urol 2007, 178:1238-1244.